Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

19-01-2016 | Ophthalmologic cancers | Article

Long-term visual outcomes in intraocular retinoblastoma with eye preservation

Journal: Clinical and Translational Oncology

Authors: A. Batra, N. Pushker, P. Venkatesh, T. Arora, R. Tewari, S. Bakhshi

Publisher: Springer International Publishing

Login to get access

Abstract

Purpose

Inconsistent data exist on long-term visual outcomes in survivors of retinoblastoma. No studies have been reported on role of ocular coherence tomography (OCT) in predicting visual acuity. We assessed visual acuity in patients with retinoblastoma treated at our center in whom affected eyes were preserved.

Methods

Patients who had completed a 2-year follow-up and were more than 5 years of age at assessment were included. Clinical data were obtained from database and factors predicting visual acuity were analyzed. OCT was performed in these patients to assess central macular thickness (CMT).

Results

Visual outcomes were assessed in 45 eyes of 43 patients, of which 38 (88 %) had bilateral retinoblastoma. The median age at diagnosis was 12 months. Sixty percent (27/45) had International classification of retinoblastoma group C or D disease with 40 % eyes showing macular lesions. The far visual acuity was better than 6/12 in 53 % (24/45), 6/12 to 6/60 in 40 % (18/45) and 6/60 in 7 % (6/60). Macular location and International classification of retinoblastoma predicted poor vision (p = 0.06 and 0.07, respectively). CMT was less than 200 μm in 3 of 36 eyes (8 %) and 1 eye showed epiretinal membrane. Radiotherapy was associated with foveal thinning (p = 0.003). Two of 3 eyes with foveal thinning had a vision of 6/60.

Conclusions

Good visual outcomes were observed in half of retinoblastoma patients treated with eye preservation. Macular location and International classification of retinoblastoma group C and D predicted poor visual acuity, while previous radiotherapy predicted foveal thinning, which was associated with poor visual acuity.
Literature
1.
Houston SK, Murray TG, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. Int Ophthalmol Clin. 2011;51:77–91.CrossRefPubMedPubMedCentral
2.
Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.CrossRefPubMed
3.
Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006;17:228–34.CrossRefPubMed
4.
Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007–2008. Curr Opin Ophthalmol. 2008;19:526–34.CrossRefPubMed
5.
Berry JL, Jubran R, Wong K, Lee TC, Murphree AL, Kim JW. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children’s Hospital Los Angeles experience. Br J Ophthalmol. 2014;98:1061–5.CrossRefPubMed
6.
Migdal C. Bilateral retinoblastoma: the prognosis for vision. Br J Ophthalmol. 1983;67:592–5.CrossRefPubMedPubMedCentral
7.
Desjardins L, Chefchaouni MC, Lumbroso L, Levy C, Asselain B, Bours D, et al. Functional results after treatment of retinoblastoma. J Publ Am Assoc Pediatr Ophthalmol Strabismus. 2002;6:108–11.CrossRef
8.
Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol Chic Ill. 1960;2005(123):1525–30.
9.
Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114:162–9.CrossRefPubMed
10.
Narang S, Mashayekhi A, Rudich D, Shields CL. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Exp Ophthalmol. 2012;40:736–42.CrossRefPubMed
11.
Hall LS, Ceisler E, Abramson DH. Visual outcomes in children with bilateral retinoblastoma. J Publ Am Assoc Pediatr Ophthalmol Strabismus. 1999;3:138–42.CrossRef
12.
Weiss AH, Karr DJ, Kalina RE, Lindsley KL, Pendergrass TW. Visual outcomes of macular retinoblastoma after external beam radiation therapy. Ophthalmology. 1994;101:1244–9.CrossRefPubMed
13.
Lam BL, Judisch GF, Sobol WM, Blodi CF. Visual prognosis in macular retinoblastomas. Am J Ophthalmol. 1990;110:229–32.CrossRefPubMed
14.
Shields CL, Mashayekhi A, Luo CK, Materin MA, Shields JA. Optical coherence tomography in children: analysis of 44 eyes with intraocular tumors and simulating conditions. J Pediatr Ophthalmol Strabismus. 2004;41:338–44.PubMed
15.
Levin LA, Gragoudas ES, Lessell S. Endothelial cell loss in irradiated optic nerves. Ophthalmology. 2000;107:370–4.CrossRefPubMed
16.
Danesh-Meyer HV. Radiation-induced optic neuropathy. J Clin Neurosci. 2008;15:95–100.CrossRefPubMed
17.
Shields CL, Manalac J, Das C, Saktanasate J, Shields JA. Review of spectral domain-enhanced depth imaging optical coherence tomography of tumors of the retina and retinal pigment epithelium in children and adults. Indian J Ophthalmol. 2015;63:128–32.CrossRefPubMedPubMedCentral